首页> 外文期刊>Pain. >Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions
【24h】

Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions

机译:安慰剂干预后,期望值和积极的情绪感受会减少正在进行的和诱发的神经性疼痛

获取原文
获取原文并翻译 | 示例
           

摘要

Research on placebo analgesia and nocebo hyperalgesia has primarily included healthy subjects or acute pain patients, and it is unknown whether these effects can be obtained in ongoing pain in patients with chronic pain caused by an identifiable nerve injury. Eighteen patients with postthoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain. Immediately after the open administration, patients rated their expected pain levels on a mechanical visual analogue scale (M-VAS). They also reported their emotional feelings via a quantitative/qualitative experiential method. Subsequently, patients rated their ongoing pain levels on the M-VAS and underwent quantitative sensory testing of evoked pain (brush, pinprick, area of hyperalgesia, wind-up-like pain). There was a significant placebo effect on both ongoing (P = .009 to .019) and evoked neuropathic pain (P = .0005 to .053). Expected pain levels accounted for significant amounts of the variance in ongoing (53.4%) and evoked pain (up to 34.5%) after the open lidocaine administration. Furthermore, patients reported high levels of positive and low levels of negative emotional feelings in the placebo condition compared with the nocebo condition (P <= .001). Pain increases during nocebo were nonsignificant (P = .394 to 1.000). To our knowledge, this is the first study to demonstrate placebo effects in ongoing neuropathic pain. It provides further evidence for placebo-induced reduction in hyperalgesia and suggests that patients' expectations coexist with emotional feelings about treatments. (c) 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
机译:安慰剂镇痛和Nocebo痛觉过敏的研究主要包括健康受试者或急性疼痛患者,尚不清楚在可识别的神经损伤引起的慢性疼痛患者的持续疼痛中能否获得这些效果。接受开胸手术后神经性疼痛的18名患者接受了安慰剂和Nocebo的操作,在这些患者中,他们接受了公开和隐蔽的缓解疼痛(利多卡因)或疼痛诱导(辣椒素)治疗的方法,以自然的疼痛史为对照。开放给药后,患者立即以机械视觉模拟量表(M-VAS)评估其预期的疼痛程度。他们还通过定量/定性的经验方法报告了他们的情感感受。随后,患者在M-VAS上评估他们持续的疼痛程度,并对诱发的疼痛(刷子,针刺,痛觉过敏区域,发条样疼痛)进行定量感觉测试。安慰剂对进行中的疼痛(P = 0.009至.019)和诱发的神经性疼痛(P = 0.0005至.053)均具有显着的安慰剂作用。利多卡因开放给药后,预期的疼痛程度占正在进行的疼痛(53.4%)和诱发性疼痛(高达34.5%)的显着差异。此外,与nocebo相比,患者在安慰剂状态下的积极情绪情绪水平较高,而负面情绪上的情绪情绪较低水平(P <= .001)。 Nocebo期间疼痛增加不明显(P = .394至1.000)。就我们所知,这是第一个证明安慰剂在进行性神经性疼痛中起作用的研究。它为安慰剂诱导的痛觉过敏减轻提供了进一步的证据,并表明患者的期望与对治疗的情感共存。 (c)2014年国际疼痛研究协会。由Elsevier B.V.发布。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号